Data Science Contractor
Magnet Biomedicine
Data Science Contractor
Magnet Biomedicine
Develops small-molecule molecular glue therapeutics
About Magnet Biomedicine
Magnet is a biotechnology company pioneering the discovery of oral molecular glues - small molecules that induce proximity between proteins to modulate their function. Our proprietary TrueGlue(TM) platform is designed to address hard-to-drug targets across cancer and immune-mediated diseases.
With support from ARCH Venture Partners, Newpath Partners, Taiho Ventures, and Eli Lilly, Magnet is advancing internal programs in oncology, immunology, and inflammation. Magnet has also entered into a collaboration and license agreement with Eli Lilly to discover, develop, and commercialize specific molecular glue therapeutics in oncology.
Position Summary
We are seeking an experienced Dotmatics/Data Science Contractor to join our CADD team. Our group sits at the intersection of laboratory science and technology, supporting the systems and applications that our chemists and biologists rely on every day to capture, manage, and act on experimental data. This is a hands-on role for someone who can contribute quickly, working directly with scientists to solve real data and workflow challenges while also building and maintaining the underlying database and software infrastructure that makes that work possible.
You will work hands-on with Dotmatics, Oracle databases, and custom software application development in a biotech/pharma R&D environment. Prior Dotmatics experience is required so you can be productive on our platform from the start.
Key Responsibilities (Specific tasks may vary depending on project and business needs)
Minimum Qualifications
Nice to Have
Who You Are
Develops small-molecule molecular glue therapeutics
Magnet Biomedicine builds small-molecule therapeutics called molecular glues that modulate protein–protein interactions to address targets that are hard to drug. Its TrueGlue platform uses proprietary chemical libraries and human biology to select targets and design glues that recruit a presenter protein to a disease-relevant target, altering function or stability rather than simply degrading it. The company differentiates itself by aiming for tissue-specific effects and a broader range of outcomes beyond degradation, backed by chemistry-driven discovery and strong industry partnerships. Its goal is to bring novel medicines to patients, focusing on oncology, cardiovascular disease, and immune disorders, with collaborations like the Lilly deal to accelerate development and commercialization.
Explore more opportunities at Magnet Biomedicine